What Fosun Pharma USA does

Fosun Pharma USA Inc. is a U.S.-focused specialty pharmaceutical company and a wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SSE: 600196, SEHK: 2196), incorporated in New Jersey in 2017 and headquartered at 104 Carnegie Center in Princeton, NJ. The company operates two business divisions: an Established Medicines division that markets a portfolio of approximately 35 specialty injectable products (covering oncology, antibiotics, cardiovascular, anesthesia, neurology, and metabolic indications) and ophthalmic solutions, and an Innovative Medicines division focused on oncology biologics led by the anti-PD-1 monoclonal antibody serplulimab for extensive-stage small cell lung cancer, with additional pipeline assets including HLX22, foritinib, and TEV-56278 (in-licensed from Teva).

The company leverages its parent group and affiliates' biopharmaceutical platform, including Henlius' vertically integrated R&D and manufacturing infrastructure with 48,000L of commercialized production capacity and 3,200+ R&D staff across 70+ in-progress innovative drug and biosimilar projects. The ASTRIDE Phase 3 bridging trial for serplulimab is active across 90+ U.S. clinical sites. Manufacturing is sourced through GMP-certified facilities in the U.S., EU, and other markets, supporting both FDA-approved specialty injectables and 505(b)(2) product launches such as the SPSB 20ml liquid product commercialized with MAIA Pharmaceuticals.

Fosun Pharma USA makes money by selling specialty pharmaceutical injectables and ophthalmics through major U.S. wholesalers (Cencora, Cardinal Health, McKesson, Morris & Dickson) to hospitals, clinics, and specialty pharmacies, and will earn licensing/commercialization economics on serplulimab upon U.S. approval (expected 2026). It also deploys capital via a joint investment vehicle with Treehill Partners into clinical-stage biopharmaceutical assets. Pricing is quote-based through distribution rather than publicly disclosed. The go-to-market combines direct field sales, customer care operations (outsourced through Eversana), business development outreach at major healthcare conferences (J.P. Morgan Healthcare Conference, ASCO, IASLC NACLC, WCLC), and licensing partnerships with non-U.S. biopharma companies seeking U.S. market access.

Name

Fosun Pharma USA

Legal name

Fosun Pharma USA, Inc.

Website

https://fosunpharmausa.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

Fosun Pharma USA is a Princeton-based specialty pharmaceutical subsidiary of Shanghai Fosun Pharmaceutical that markets FDA-approved specialty injectable and ophthalmic products through major U.S. wholesalers while building an oncology biologics pipeline, notably the anti-PD-1 monoclonal antibody serplulimab for U.S. launch in 2026.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Specialty pharmaceutical injectables
• Ophthalmic solutions
• Oncology biopharmaceuticals
• 505(b)(2) products
• Hospital pharmaceutical distribution

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Supply Chain, Technology or R&D, Operations

Revenue model

1. Specialty Injectables and Ophthalmics Sales: Direct sales of specialty pharmaceutical injectable products and ophthalmics to U.S. hospitals, clinics, and specialty pharmacies through the company's commercial infrastructure. Products include Arformoterol Tartrate Inhalation Solution, Azelastine Hydrochloride Ophthalmic, Bimatoprost, Caspofungin, Cisplatin, and other injectables distributed through major wholesalers (Cencora, Cardinal, McKesson, Morris & Dickson).
2. Serplulimab U.S. Commercialization (License from Henlius): Exclusive license agreement with Shanghai Henlius Biotech for commercialisation of anti-PD-1 monoclonal antibody serplulimab in the United States. Fosun Pharma USA has the right to commercialise upon approval, while Henlius retains responsibility for development, manufacturing, and supply. Expected launch in 2026.
3. 505(b)(2) Product Commercialization (SPSB): Joint commercialization of Sodium Phenylacetate and Sodium Benzoate (SPSB) 20ml liquid product with MAIA Pharmaceuticals. Fosun Pharma USA holds exclusive commercial rights in the U.S. market. This was described as the first of many 505(b)(2) products to be launched.
4. Capital Investment Returns (Treehill Joint Vehicle): Jointly operating vehicle with Treehill Partners for investment in clinical-stage assets, focusing on mid-to-late stage assets and non-U.S. clinical-stage biopharma assets seeking U.S. market access. First investments targeted during 2024.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Fosun Pharma USA is a U.S.-focused specialty pharmaceutical company that markets specialty injectable pharmaceuticals and ophthalmic products to U.S. hospitals, clinics, and specialty pharmacies through major wholesalers, while building a portfolio of innovative oncology and immunology products (anchored by serplulimab) for U.S. commercialization through licensing and development partnerships with its parent group, Henlius, Teva, and other biopharmaceutical collaborators.

Product overview

Fosun Pharma USA is a US-focused specialty pharmaceutical company operating two divisions: Established Medicines and Innovative Medicines. The Established Medicines division markets a portfolio of specialty pharmaceutical injectable products and ophthalmic solutions including injectables (chemotherapy agents, antibiotics, cardiovascular drugs, anesthetics, neurological medications), ophthalmic drops (for glaucoma, allergies, inflammation), and 505(b)(2) products. The Innovative Medicines division focuses on oncology with lead asset serplulimab (anti-PD-1 monoclonal antibody) for extensive-stage small cell lung cancer. The company also has partnerships for products including Otezla (psoriasis) and Parsabiv (chronic kidney disease), and a strategic partnership with Teva for TEV-56278 (anti-PD1-IL2 therapy) in immuno-oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• Serplulimab Novel, fully humanized anti-PD-1 IgG4 monoclonal antibody being evaluated in combination with chemotherapy for extensive-stage small cell lung cancer (ES-SCLC) through the ASTRIDE bridging study across 90+ U.S. clinical trial sites; received orphan drug designation from FDA and European Commission, with demonstrated mOS of 15.8 months in the ASTRUM-005 Phase 3 trial.
• Guanfacine Extended-Release Tablets, USP Extended-release tablets available in 1mg, 2mg, 3mg, and 4mg strengths indicated for hypertension management; distributed to U.S. hospitals, clinics, and pharmacies through major wholesalers.
• Arformoterol Tartrate Inhalation Solution Inhalation solution for respiratory care at 15 mcg/2 mL strength, available in 30-count and 60-count sterile unit-dose vials; marketed to U.S. healthcare providers through major wholesalers.
• Azelastine Hydrochloride Ophthalmic Solution Ophthalmic solution 0.05% concentration in 6mL bottle for allergic eye conditions; distributed through major wholesalers to specialty pharmacies and hospitals.
• Bimatoprost Ophthalmic Solution Ophthalmic solution 0.03% concentration available in 2.5mL, 5mL, and 7.5mL dropper bottles for ophthalmology indications; distributed to specialty pharmacies and clinics.
• Bromfenac Ophthalmic Solution Ophthalmic NSAID solution 0.09% concentration in 1.7mL dropper for inflammation following cataract surgery.
• Dorzolamide Hydrochloride Ophthalmic Solution, USP Carbonic anhydrase inhibitor ophthalmic solution 2% concentration in 10mL bottle indicated for glaucoma.
• Timolol Maleate Ophthalmic Gel Forming Solution Beta-blocker ophthalmic gel forming solution available in 0.25% and 0.5% concentrations in 5mL bottles for glaucoma management.
• Cisplatin Injection Platinum-based chemotherapy agent available in 50mg/50mL and 100mg/100mL multiple-dose vials for oncology administration in hospital settings.
• Oxaliplatin Injection, USP Platinum-based chemotherapy agent available in 50mg/10mL and 100mg/20mL single-dose vials for oncology administration.
• Labetalol Hydrochloride Injection, USP Alpha/beta-blocker for hypertension management available in 100mg/20mL and 200mg/40mL multiple-dose vials, including NovaPlus formulation.
• Metoprolol Tartrate Injection, USP Beta-blocker for cardiovascular conditions in 5mg/5mL single-dose vials.
• Ketorolac Tromethamine Injection, USP Non-opioid analgesic available in 15mg/mL, 30mg/mL, and 60mg/2mL single-dose vials for pain management.
• Bupivacaine Hydrochloride Injection, USP Local anesthetic available in 0.25% (25mg/10mL) and 0.5% (50mg/10mL) single-dose vials for surgical and procedural anesthesia.
• Caspofungin Acetate for Injection Antifungal agent 50mg/vial single-dose vial indicated for invasive fungal infections.
• Ertapenem for Injection Carbapenem antibiotic 1g/vial for mixed aerobic-anaerobic bacterial infections.
• Doxycycline for Injection, USP Tetracycline antibiotic 100mg/vial for severe infections, supplied in 5-pack cartons.
• Polymyxin B for Injection, USP Polymyxin antibiotic 500,000 units/vial for gram-negative bacterial infections.
• Tobramycin for Injection, USP Aminoglycoside antibiotic 1.2g/vial for serious gram-negative bacterial infections.
• Voriconazole for Injection Azole antifungal 200mg/vial for invasive aspergillosis and serious fungal infections.
• Calcitriol Injection, USP Vitamin D analog 1mcg/mL for management of hypocalcemia in dialysis patients.
• Melphalan Hydrochloride for Injection Alkylating agent 50mg with diluent indicated for multiple myeloma and ovarian cancer.
• Clofarabine Injection Nucleoside analog 20mg/20mL for pediatric relapsed or refractory acute lymphoblastic leukemia.
• Dexrazoxane for Injection Cardioprotective agent for anthracycline-induced cardiotoxicity, available in 250mg and 500mg vials.
• Ziprasidone Mesylate for Injection Atypical antipsychotic 20mg/vial for acute agitation in schizophrenia, including NovaPlus formulation.
• Zoledronic Acid Injection Bisphosphonate 5mg/100mL single-dose bag for hypercalcemia of malignancy and bone metastases.
• Etomidate Injection, USP Anesthetic agent available in 20mg/10mL and 40mg/20mL single-dose vials for procedural sedation.
• Lacosamide Injection, USP Antiepileptic 200mg/20mL indicated for partial-onset seizures, supplied in 5-pack cartons.
• Levothyroxine Sodium for Injection Thyroid hormone 100mcg/vial indicated for hypothyroidism and myxedema coma.
• Thiamine Hydrochloride Injection, USP Vitamin B1 200mg/2mL indicated for thiamine deficiency and Wernicke-Korsakoff syndrome.
• Ondansetron Injection, USP Antiemetic available in 4mg/2mL and 40mg vial formulations for prevention of nausea and vomiting.
• Dicyclomine Hydrochloride Injection, USP Anticholinergic 20mg/2mL for irritable bowel syndrome relief.
• Prochlorperazine Edisylate Injection, USP Antiemetic/antipsychotic 10mg/2mL for severe nausea and psychotic disorders.
• Sincalide for Injection Cholecystokinetic agent 5mcg/vial for stimulation of gallbladder contraction and bile secretion.
• Sodium Phenylacetate and Sodium Benzoate Injection (SPSB) 20mL Nitrogen binding agent 10%/10% concentration in 20mL for urea cycle disorders; available in 20ml and 50ml vial sizes, the only FDA-approved 20ml SPSB product on the U.S. market.
• Moxifloxacin Ophthalmic Solution, USP Fluoroquinolone ophthalmic solution 0.5% in 3mL dropper for bacterial conjunctivitis.

Quantifiable outcome

• Serplulimab demonstrated mOS of 15.8 months in ASTRUM-005 Phase 3 trial for ES-SCLC, significantly improving over chemotherapy alone.
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered minor, core/flagship and strategic.

• MAP InternationalminorOthers · 8 July 2025Global collaboration to grow access to essential pain relief in underserved communities. Fosun Pharma USA donates Ketorolac Tromethamine Injection, USP through MAP's international distribution network serving 300 on-the-ground partners and volunteer medical mission groups. Shipments sent to communities in Dominican Republic, Nigeria, Haiti, and Honduras. In 2024, MAP delivered over 47 million treatments to 92 countries. Marks first step in long-term collaboration for health equity.
• Teva Pharmaceutical Industries Ltd.core/flagshipStrategic or Co-development Partner · 16 June 2025Strategic partnership for the development of investigational TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy. Fosun Pharma is granted exclusive license to develop, manufacture, and commercialize TEV-56278 in Chinese mainland, Hong Kong SAR, Macau SAR, Taiwan region and select Southeast Asian countries. Teva retains all development, manufacturing, and commercialization rights in the rest of the world. The partnership leverages Teva's internally developed ATTENUKINE technology with Fosun Pharma's strong oncology development experience and commercial capabilities in China.
• Fakeeh Care GroupstrategicStrategic or Co-development Partner · 28 April 2025Strategic partnership to advance cell and gene therapy and tele-diagnostics in Saudi Arabia. Part of Fakeeh Care Group's vision to accelerate healthcare innovation in Saudi Arabia and align with Saudi Vision 2030. Fosun Pharma is an international frontrunner in biopharmaceuticals, CAR-T therapies and gene therapy. The MoU outlines collaboration to reshape the healthcare landscape in the Kingdom and the region, positioning Saudi Arabia as a regional hub for healthcare innovation.
• Shanghai Henlius Biotech, Inc.core/flagshipStrategic or Co-development Partner · 7 January 2023Exclusive license agreement for commercialisation of anti-PD-1 monoclonal antibody serplulimab in the United States. Fosun Pharma USA has the right to commercialise upon approval, while Henlius retains responsibility for development, manufacturing, and supply. This is a core partnership marking an important milestone for Fosun Pharma's U.S. development. The partnership leverages Henlius' vertically integrated biopharmaceutical platform with high-efficiency innovation embedded throughout the product lifecycle including R&D, manufacturing, and commercialisation.
• MAIA Pharmaceuticals, Inc.core/flagshipStrategic or Co-development Partner · 26 September 2022Joint commercialization of Sodium Phenylacetate and Sodium Benzoate (SPSB) 20ml liquid product, the only FDA-approved 20ml SPSB product. Fosun Pharma USA holds exclusive commercial rights in the U.S. market. This was described as the first of many 505(b)(2) products to be launched by Fosun Pharma USA, addressing product wastage concerns in pediatric settings and reducing unnecessary healthcare spending.
• Amgen Inc.strategicStrategic or Co-development Partner · 27 June 2022Collaboration and license agreement for Fosun Pharma (not specifically USA) for the commercialization of Amgen's Otezla® (apremilast) and Parsabiv® (etelcalcetide) in Chinese Mainland. Otezla® was approved by NMPA in August 2021 for treatment of adult patients with moderate to severe plaque psoriasis. Parsabiv® is approved by EMA and FDA for treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis. Enables Amgen to leverage Fosun Pharma's commercial capabilities within China.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Amneal Pharmaceuticals: U.S.-headquartered specialty and generic pharmaceutical company with a large specialty injectables and ophthalmics portfolio distributed through the same Big-3 wholesaler channel. Closely comparable in product mix, distribution model, and customer base (hospitals, clinics, specialty pharmacies).
• Hikma Pharmaceuticals: Jordan-headquartered specialty injectable and generics company with a large U.S. hospital injectables business. Comparable on product categories, wholesaler distribution model, and customer mix (U.S. hospitals and clinics).
• AuroMedics (Aurobindo Pharma USA): U.S. specialty injectables division of Aurobindo Pharma. Competes head-to-head with Fosun Pharma USA across hospital injectable SKUs (anti-infectives, cardiovascular, oncology supportive care) and shares the same FDA-approved generic injectable commercial playbook.
• Dr. Reddy's Laboratories (U.S. operations): India-headquartered global pharmaceutical company with a substantial U.S. specialty generics and injectables franchise. Directly comparable as a non-U.S. parent building a U.S. hospital injectables and specialty portfolio through distribution partnerships.
• Sagent Pharmaceuticals: U.S.-focused specialty injectable pharmaceutical company. Highly comparable on product mix (sterile injectables including oncology, anti-infectives) and on its strategy of marketing specialty injectables through major wholesalers to U.S. hospitals.
• Zydus Pharmaceuticals (USA): U.S. subsidiary of Zydus Cadila, marketing specialty generics, injectables, and ophthalmics. Comparable as a foreign-owned pharma group building U.S. presence through specialty injectable and ophthalmic product launches via the standard wholesaler channel.
• Lupin Pharmaceuticals: India-headquartered pharmaceutical company with a meaningful U.S. specialty injectables and ophthalmics portfolio. Comparable in product categories, distribution through major wholesalers, and cross-border supply model.

Broad incumbents

• Teva Pharmaceutical Industries: Global leader in generic and specialty pharmaceuticals with a U.S. hospital injectables presence and active oncology pipeline. Also a direct strategic partner to Fosun Pharma on TEV-56278. Comparable on both the specialty injectables business and the innovative medicines (immuno-oncology) overlap.
• Hospira / Pfizer Hospital: Pfizer's hospital injectables business (built on the Hospira acquisition) is the dominant U.S. specialty injectable franchise. Direct overlap on most established-medicines product categories (Cisplatin, Caspofungin, Ertapenem, Voriconazole, etc.), though as part of a much larger global portfolio.

Emerging players

• Henlius (Shanghai Henlius Biotech): Sister company under Fosun Pharma Group and the originator/licensor of serplulimab to Fosun Pharma USA. A directly comparable biopharma with biosimilar and innovative mAb capabilities, GMP-certified manufacturing, and a clinical pipeline that overlaps Fosun Pharma USA's U.S. commercial strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/fosun-pharma-usa-inc

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fosun Pharma USA